This Article Full Text Full Text (PDF) All Versions of this Article: 45/1/46    most recent 01.HYP.0000151324.05355.1cv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kizer, J. R. Articles by Devereux, R. B. Search for Related Content PubMed PubMed Citation Articles by Kizer, J. R. Articles by Devereux, R. B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATENOLOL LOSARTAN POTASSIUM Medline Plus Health Information High Blood Pressure Stroke Related Collections Clinical Studies Cerebrovascular disease/stroke Primary prevention Secondary prevention

(Hypertension. 2005;45:46.)
© 2005 American Heart Association, Inc.

Scientific Contributions

Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol

The Losartan Intervention For Endpoint Reduction in Hypertension Study

Jorge R. Kizer; Björn Dahlöf; Sverre E. Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H. Lindholm; Markku S. Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Kristian Wachtell; Jonathan M. Edelman; Steven M. Snapinn; Katherine E. Harris; Richard B. Devereux

From the Weill Medical College of Cornell University (J.R.K., R.B.D.), New York, NY; Sahlgrenska/Östra University Hospital (B.D.), Gothenburg, Sweden; Ullevaal University Hospital (S.E.K.), Oslo, Norway; University of Michigan (S.J.), Ann Arbor; City Hospital (G.B.), Birmingham, UK; Karolinska University Hospital (U.d.F.), Stockholm, Sweden; Helsinki University Central Hospital (F.F., M.S.N.), Finland; Glostrup University Hospital (H.I., K.H.), Copenhagen, Denmark; Merck Research Laboratories Scandinavia (K.K.), Stockholm, Sweden; Viborg Hospital (O.L.-P.), Denmark; Umeå University (L.H.L.), Sweden; Haukeland University Hospital (P.O.), Bergen, Norway; University of Alabama (S.O.), Birmingham; The Nordic School of Public Health (H.W.), Gothenburg, Sweden; and Merck & Co, Inc (J.M.O., S.M.S., K.E.H.), Whitehouse Station, NJ.

Correspondence to Dr Jorge R. Kizer, Box 222, 525 E 68th St, New York, NY 10021. E-mail jok2007{at}med.cornell.edu

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the ß-blocker atenolol. We conducted secondary analyses in LIFE to determine the extent to which the cerebrovascular benefits of losartan apply to different clinical subgroups and stroke subtypes and to assess the dependence of these benefits on baseline and time-varying covariates. Among 9193 hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy, random allocation to losartan-based treatment lowered the risk of fatal (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.43 to 0.96; P=0.032) and atherothrombotic stroke (HR, 0.72; 95% CI, 0.59 to 0.88; P=0.001) compared with atenolol-based therapy. Although comparable risk reductions occurred for hemorrhagic and embolic stroke, these were not statistically significant. The number of neurological deficits per stroke was similar, but there were fewer strokes in the losartan group for nearly every level of stroke severity. Effects were consistent in all clinical subgroups except for those defined by age and ethnicity. The benefits of losartan on all strokes were independent of baseline and time-varying risk factors, including blood pressure. The number needed to treat for 5 years to prevent 1 stroke was 54 for the average participant, declining to 25, 24, and 9 for patients with cerebrovascular disease, isolated systolic hypertension, and atrial fibrillation, respectively. In conclusion, substantial cerebrovascular benefit could be realized with the institution of losartan-based therapy over conventional therapy among hypertensive patients with left ventricular hypertrophy across the spectrum of cardiovascular risk.

Key Words: population • drug therapy • clinical trials • angiotensin antagonists • hypertrophy • stroke

This article has been cited by other articles:

				D. Sorescu Smad3 Mediates Angiotensin II- and TGF-{beta}1-Induced Vascular Fibrosis: Smad3 Thickens the Plot Circ. Res., April 28, 2006; 98(8): 988 - 989. [Full Text] [PDF]

				M. Volpe, G. Tocci, and E. Pagannone Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System. J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S36 - S43. [Abstract] [Full Text] [PDF]

				M. Kirby Has ASCOT signalled the end for beta blockers as first-line antihypertensive agents? The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 100 - 102. [Abstract] [PDF]